---
title: Development of a Ligand for In Vivo Imaging of Mutant Huntingtin in Huntington’s Disease
description: "hide gateway
Read our publication. Fighting Huntington's Disease through the development of a Ligand for in Vivo Imaging of Mutant Huntingtin. Contact Evotec to learn more!"
image: https://news.cyprotex.com/hubfs/HuntingtonsDisease-1.jpg
---

[![Cyprotex | The Leading ADME-Tox Specialist](https://news.cyprotex.com/hs-fs/hubfs/cyprotex%20logo.png?width=224&height=62&name=cyprotex%20logo.png "Cyprotex | The Leading ADME-Tox Specialist")](https://www.cyprotex.com/)

# Science Pool

# Development of a Ligand for In Vivo Imaging of Mutant Huntingtin in Huntington’s Disease

Posted by [Evotec](https://news.cyprotex.com/sciencepool/author/evotec) on Mar 10, 2022 10:24:55 AM

Huntington´s Disease (HD) is a hereditary neurodegenerative disorder that is caused by a mutation in the huntingtin gene (mHTT) leading to deposition of pathologic protein aggregates in the brain.

This paper focuses on:

- Visualization of mHTT aggregate expression by positron emission tomography (PET) in rodent HD model
- Utility of the previously described novel PET imaging ligand CHDI-180 for detection of mHTT in rodent and post-mortem human HD brain
- Ability of CHDI-180 to serve as functional response indicator for mHTT lowering therapies

[GET THE PAPER](https://www.science.org/doi/abs/10.1126/scitranslmed.abm3682)

 Tags: [Medicinal Chemistry](https://news.cyprotex.com/sciencepool/tag/medicinal-chemistry), [Articles & Whitepapers](https://news.cyprotex.com/sciencepool/tag/articles-whitepapers), [Proteomics, Metabolomics & Biomarkers](https://news.cyprotex.com/sciencepool/tag/proteomics-metabolomics-biomarkers)